Design and Synthesis of p-hydroxybenzohydrazide Derivatives for their Antimycobacterial Activity
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The main mycobacterial infection in human is tuberculosis caused by Mycobacterium tuberculosis. Tuberculosis is the leading infectious cause of death in the world. Therefore there is continuing and compelling need for new and improved treatment for tuberculosis. The entire logic towards design of new compounds containing 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide moiety is basically for superior antimycobacterial activity. The recent advances in QSAR and computer science have provided a systematic approach to design a structure of any compound and further, the biological activity of the compound can be predicted before synthesis. The 3D-QSAR studies for the set of 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide and their derivatives were carried out by using V-life MDS (3.50). The various statistical methods such as Multiple Linear Regression (MLR), Partial Least Square Regression (PLSR), Principle Component Regression(PCR) and K nearest neighbour (kNN) were used. The kNN showed good results having cross validated r2 0.9319, r2 for external test set 0.8561 and standard error of estimate 0.2195. The docking studies were carried out by using Schrodinger GLIDE module which resulted in good docking score in comparison with the standard isoniazid. The designed compounds were further subjected for synthesis and biological evaluation. Antitubercular evaluation of these compounds showed that (4.a), (4.d) and (4.g) found as potent inhibitor of H37RV.
Abstract
The main mycobacterial infection in human is tuberculosis caused by Mycobacterium tuberculosis. Tuberculosis is the leading infectious cause of death in the world. Therefore there is continuing and compelling need for new and improved treatment for tuberculosis. The entire logic towards design of new compounds containing 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide moiety is basically for superior antimycobacterial activity. The recent advances in QSAR and computer science have provided a systematic approach to design a structure of any compound and further, the biological activity of the compound can be predicted before synthesis. The 3D-QSAR studies for the set of 4-hydroxy-N'-(1,3-thiazoldin- 2-yldene)benzohydrazide and their derivatives were carried out by using V-life MDS (3.50). The various statistical methods such as Multiple Linear Regression (MLR), Partial Least Square Regression (PLSR), Principle Component Regression(PCR) and K nearest neighbour (kNN) were used. The kNN showed good results having cross validated r2 0.9319, r2 for external test set 0.8561 and standard error of estimate 0.2195. The docking studies were carried out by using Schrodinger GLIDE module which resulted in good docking score in comparison with the standard isoniazid. The designed compounds were further subjected for synthesis and biological evaluation. Antitubercular evaluation of these compounds showed that (4.a), (4.d) and (4.g) found as potent inhibitor of H37RV.
참고문헌 (38)
- Delgado, J. N, "Wilson and Gisvold’s Text-book of Organic Medicinal and Pharmaceutical Chemistry,11th ed", pp.1~3 (2002), Lippincott-Raven
- Peter, G, "Guide Book on Molecular Modeling In Drug Design, 1st ed", pp.216~232 (1966), Academic Press
- Gerhard, K, "Computer Aided Molecular Designs, 1st ed", pp.473~498 (1999), Harward Press
- Carter, R. C, , Annual Reports in Medicinal Chemistry, 33, pp.397~ (1998)
- Propst, C. L, "Computer Aided Drug Design Methods and Application", pp.12~ (1989), Marcel Dekker
- Kulkarni, V. M, "Textbook of Drug Design,2nd ed", pp.189~211 (2003), Nirali Prakashan
- Claude, C. N, "Guidebook on Molecular Modeling In Drug Design, 1st ed", pp.94~100 (2009), Elsevier
- Richet, M. C., , Compt. Rend. Soc. Biol, 45, pp.885~ (1893)
- Overton, E, "Studies on Narcosis" (1991), Chapman and Hall
- Rao, R. P, , J. Indian. Chem. Soc, 38, pp.784~ (1961)
- Wilson, F. J, , J. Chem. Soc, 121, pp.870~ (1922)
- Bhole, R. P, , QSAR Comb. Sci, 28, pp.405~ (2009)
- Joshi, S. D, , Eur. J. Med. Chem, 43, pp.1989~ (2008)
- Rollas, S, , Eur. J. Med. Chem, 34, pp.1093~ (1999)
- Vijaya Raj K. K, , Eur. J. Med. Chem, 42, pp.425~ (2007)
- Maccari, R, , Bioorg. Med. Chem, 15, pp.2509~ (2005)
- Zhong, X, , Bioorg. Med. Chem, 17, pp.3774~ (2007)
- Osyanin, V. A, , Rus. J. Gen. Chem, 75, pp.111~ (2005)
- Patole, J, , Bioorg. Med. Chem, 13, pp.51~ (2003)
- Koschucharov, R, , Pharmazie, 15, pp.492~ (1960)
- Paigeen, K., , Prog. Nucleic. Acid. Res. Mol. Biol, 37, pp.155~ (1989)
- Ho, J, , Eur. J. Clin. Invest, 16, pp.361~ (1986)
- Inanov, N, , Chem. Abst, 53, pp.15038~ (1959)
- Mazouz, F, , J. Med. Chem, 36, pp.1157~ (1993)
- "Ernest, Carron MC. U.S. Patent 3290213", ~
- Davidson, P. T, , Drugs, 43, pp.651~ (1993)
- Vincent, T. A., , Int. J. Antimicrob. Agents, 16, pp.317~ (2000)
- Tan, Y. T, , Mol. Med. Today, 6, pp.309~ (2000)
- "PHASE 2.0, Schrodinger" (2006), LLC
- "Ligprep 2.0, Schrodinger" (2006), LLC
- Ke, Y. S, , Eur. J. Med. Chem, 43, pp.1~ (2008)
- "MacroModel 9.1, Schrodinger" (2006), LLC
- Halgren, T. A, , J. Comput. Chem, 17, pp.520~ (1996)
- "MacroModel 2.0, User Manual" (2006), LLC
- Chang, G, , J. Am. Chem. Soc, 111, pp.4379~ (1989)
- Kolossvary, I, , J. Am. Chem. Soc, 118, pp.5011~ (1996)
- "SMARTS-Language for Describing Molecular Patterns", Daylight Chemical Information Systems, Inc